<DOC>
	<DOCNO>NCT00780975</DOCNO>
	<brief_summary>This study test safety efficacy investigational chemotherapy agent patient advanced prostate cancer . Subjects meet entry criterion sign informed consent enrol study . Participants require attend regular clinic visit receive study medication status monitor . A detailed explanation provide investigator conducting study .</brief_summary>
	<brief_title>A Study Aplidin ( Plitidepsin ) Subjects With Advanced Prostate Cancer</brief_title>
	<detailed_description>Prostate cancer common non-cutaneous cancer diagnose men United States . The majority death occur men androgen-independent prostate cancer [ AIPC ] . Although 80 % men advance cancer initially respond androgen ablation disease regression stabilization , malignancies become resistant therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Written inform consent start studyspecific procedure . If patient unable give consent , may obtain patient 's legal representative accordance local law regulation . 2 . Men castrate metastatic adenocarcinoma prostate , follow characteristic : Confirmed pathological diagnosis . Metastatic disease ( radiologically document ) . All patient chemical castration must serum testosterone level 50 ng/ml . There need document serum testosterone patient prior surgical castration2 . Baseline PSA &gt; 5 ng/ml ( accord recommendation ProstateSpecific Antigen Working Group2 ) . Androgenindependent progressive disease , define detectable , rise PSA two consecutive measurement least one week apart : If PSA respond prior therapy , progression occur PSA 50 % nadir level . If PSA respond prior therapy , progression occur PSA increase 25 % pretreatment level . In case , increase absolute value PSA level must least 5 ng/ml , must confirm second measurement minimum 1 week later . Patients must receive prior docetaxelbased chemotherapy . 3 . Recovery toxicity derive previous treatment . The presence alopecia NCICTC grade &lt; 2 sensitive peripheral neuropathy allow . 4 . Age &gt; 18 year . 5 . Performance status ( ECOG ) &lt; 2 . 6 . Life expectancy &gt; 3 month . 7 . Adequate renal , hepatic , bone marrow function ( assessed &lt; 14 day inclusion study ) : Neutrophil count ³ 1.5 x 109/L . Platelet count ³ 100 x 109/L . Hemoglobin &gt; 9 g/dl . Creatinine clearance ³ 40 ml/min ( calculate Cockcroft Gault formula ) , see Appendix 3 . Serum bilirubin * 1.5 mg/dl . AST , ALT &lt; 2.5 x ULN ( &lt; 5 x ULN case liver metastasis ) . Albumin &gt; 25 g/L . 8 . Left ventricular ejection fraction within normal limit 1 . Prior therapy Aplidin® . 2 . Concomitant therapy antitumor agent , include glucocorticoid daily dose great 10 mg prednisone equivalent , except indicated symptom control , provide disease progression document steroid . 3 . Small cell carcinoma prostate . 4 . More two previous line systemic therapy patient 's castrate metastatic disease , consider biological agent chemotherapy systemic therapy . 5 . Patients progressive measurable disease without increase PSA value ( accord consensus recommendation ) consider eligible . 6 . Washout period le : 6 week last dose nitrosourea high dose chemotherapy 4 week last dose chemotherapy biological agent 6 week end treatment extensive external beam radiation ( 25 % bone marrow distribution ) radionuclide therapy . 4 week end treatment palliative radiation involve less 25 % bone marrow reserve . 4 week major prior surgery 30 day receive investigational product 7 . Men reproductive potential use effective contraceptive method , consider complete abstinence intercourse throughout treatment study drug least 6 month completion premature discontinuation study effective contraceptive method , sure patient 's female partner become pregnant . 8 . History another neoplastic disease . The exception : 8.1 Nonmelanoma skin cancer . 8.2 Any cancer curatively treat evidence disease least 10 year . 9 . Known symptomatic cerebral leptomeningeal involvement . 10 . Other relevant disease adverse clinical condition : History presence unstable angina , myocardial infarction , valvular heart disease congestive heart failure . Previous mediastinal radiotherapy . Uncontrolled arterial hypertension despite optimal medical therapy . Previous treatment doxorubicin cumulative dos excess 400 mg/m² . Symptomatic arrhythmia arrhythmia require treatment . Abnormal ECG detail : QT interval prolongation : QTc &gt; 480 msec . Left ventricular hypertrophy : Sokolow Index : ( R V5 V6 ) + S V1 ) &gt; 3.5mv . Left bundlebranch block : Complete : QRS &gt; 0.12 sec . No Q wave see lead V5 V6 . A notched R wave see leave lead notch S wave right side lead . Right bundlebranch block : Complete : QRS &gt; 0.12 sec . Secondary R ( R ' ) wave lead V1V2 . Slurred S wave lead D1 , avL , V5 V6 . Seconddegree atrioventricular ( av ) block : Mobitz I AV block , Wenckebach block : Progressive prolongation PR interval cause progressive RR interval shorten P wave fail conduct ventricle . The RR interval contain block P wave short sum twPP interval . Mobitz II AV block characterize sudden unexpected block P wave without variation prolongation PR interval . It 2:1 , 3:1 , 4:1 etc . Thirddegree atrioventricular block : P wave QRS complex without mutual relationship . P wave rate great QRS complex . Ischemia , injury infarction : Subendocardial ischemia . Symmetrical T wave increase amplitude . Subepicardial ischemia . Inverted symmetrical T wave . Subendocardial injury . ST segment depression ( horizontal descending ) . Subepicardial injury . ST segment elevation upper convexity . Infarction necrosis . Q wave voltage great 25 % R wave voltage . Duration Q wave 0.04 sec History significant neurological psychiatric disorder . Active infection ; infection HIV , HBV HCV . HIV , HBV HCV test require unless infection clinically suspect . Myopathy clinical situation cause significant persistent elevation CK ( &gt; 2.5 ULN two different determination perform one week apart ) . Significant nonneoplastic liver disease ( e.g. , cirrhosis , active chronic hepatitis ) . Limitation patient 's ability comply treatment followup protocol . Uncontrolled endocrine disease ( e.g . diabetes mellitus , hypothyroidism hyperthyroidism ) ( i.e . require relevant change medication within last month , hospital admission within last 3 month ) . 11 . Known hypersensitivity Aplidin® , mannitol , cremophor EL , ethanol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Aplidin</keyword>
	<keyword>Plitidepsin</keyword>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
</DOC>